The Company has received an order at an initial value of 10-20 kSEK from an organisation that has experienced limitations with established analytical methods, including disruptive tissue autofluorescence and limited sensitivity in the detection of biomarkers. Against this background, the customer intends to use Lumito’s SCIZYS product to enable measurement of low levels of biomarkers in tissue samples, as well as to achieve an efficient and simplified workflow.

”Although the order value at this stage is limited, we view the transaction as an important step in Lumito’s commercial development and a confirmation that we are doing the right things. Our Scan-as-a-Service offering lowers the threshold for customers to start using our technology and creates conditions for long-term relationships and recurring revenue. The order confirms both our product and our business model and provides us with valuable experience ahead of continued commercialisation”, säger Sanna Wallenborg, VD för Lumito.